Scalability study on [133La]LaCl3 production with a focus on potential clinical applications
In this article we present an overarching study on <sup>133</sup>La production, from the radiation parameters optimization to a clinical dose estimation. Lanthanum-133 activities in the GBq range could be produced, formulated as [<sup>133</sup>La]LaCl<sub>3</sub> with high quality regarding radiolabeling and radionuclide purity. We believe that increasing the <sup>133</sup>La availability will further promote the development of radiopharmaceuticals based on macropa or other chelators suitable for <sup>225</sup>Ac.
Authors
- Constantin Mamat (ORCID: https://orcid.org/0000-0003-1906-3186)
- Magdalena Blei (ORCID: https://orcid.org/0009-0009-1358-3560)
- Martin Walther (ORCID: https://orcid.org/0000-0002-0474-8492)
- Klaus Kopka (ORCID: https://orcid.org/0000-0003-4846-1271)
- Santiago Andrés Brühlmann (ORCID: https://orcid.org/0000-0002-7840-6858)
- Martin Kreller (ORCID: https://orcid.org/0000-0003-2424-3202)
- Robert Freudenberg (ORCID: https://orcid.org/0000-0002-1970-6957)
Institutions
- German Cancer Research Center (DE)
- Helmholtz-Zentrum Dresden-Rossendorf (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1186/s41181-024-00292-w
- Citations
- 6
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.43